eClinical Technology and Industy News

Hope Biosciences Stem Cell Research Foundation Selects Phlexglobal to Support Rapid, Compliant Investigational New Drug Application for COVID-19 Therapy

Excerpt from the Press Release:

Phlexglobal, a leading innovative technology and services provider for the life sciences industry, today announces that Hope Biosciences Stem Cell Research Foundation has selected Phlexglobal’s advanced SaaS solution, PhlexSubmission, to enhance the efficiency and quality of its eCTD submissions process. As an organization dedicated to advancing research through innovative protocols using the latest technology, the Foundation was looking for the most advanced Electronic Common Technical Document (eCTD) software partner to support its mission. PhlexSubmission – a robust, highly configurable, and easy-to-use publishing engine for electronic submissions such as eCTD, NeeS, and VNeeS – was the clear winner.

“We launched the Foundation this year to accelerate translational research in regenerative medicine so that therapies could be delivered to patients faster, ultimately by delivering high-quality data for quicker approval,” noted Donna Chang, Founder, Hope Biosciences Stem Cell Research Foundation. “With three COVID-19 protocols already approved, our team needed a solution provider to match our dedication to speed and quality, and whose submissions technology could meet our stringent requirements and growing trial portfolio. We found the right partner in Phlexglobal.”

Click the button below to continue reading the Press Release:

Continue Reading The Article

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?